Anastrozole

—

evidence score

hormonal

Prescription Only

ArimidexAIaromatase inhibitor+1 more

Anastrozole is a third-generation non-steroidal aromatase inhibitor (AI) FDA-approved for hormone receptor-positive breast cancer. In male performance medicine and TRT, it is used to control estradiol elevation from testosterone aromatization. Excessive estrogen during TRT or anabolic steroid use causes water retention, gynecomastia, mood instability, and sexual dysfunction. However, estrogen is essential for men too — bone density, libido, cardiovascular health, and joint function all require adequate estrogen. Anastrozole dosing requires careful titration to labs; over-suppression of estrogen ("crashing estrogen") is common and causes significant symptoms.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Research Sync

Not synced yet

Dosing

Typical

0.5 mg

0.25 mgRange1 mg

Frequencyevery other day to twice weekly

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~50 hours

OnsetEstradiol reduction within 24-48 hours; clinical symptom relief within 1-2 weeks

DurationOngoing aromatase inhibition during use; estrogen recovery 2-3 weeks after stopping

Routes

oral

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(40%)—

Quality(30%)—

Sample Size(10%)—

Consistency(10%)—

Replication(5%)—

Recency(5%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Anastrozole is currently categorized as a hormonal compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Reversible competitive inhibitor of aromatase (CYP19A1); blocks conversion of testosterone → estradiol; reduces circulating estrogen by 70-80% in men

Practical Context

Strongest current signals

No indexed study summaries yet.